Pfizer Divests Its Swine Vaccine Business To Harbin Pharmaceutical Group In China As Condition Of $68 Billion Merger With Wyeth

SHANGHAI - Pfizer recently completed the divestment of its swine vaccine business in China to local company Harbin Bio-Vaccine, an animal health subsidiary of Harbin Pharmaceutical Group